Latest:
Dr. Riedel on the Challenges of Diagnosing and Treating Patients With Desmoid Tumors
Richard F. Riedel, MD, discusses the challenges of diagnosing and treating patients with desmoid tumors.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Richard Finn, MD
Latest:
Importance of Real-World Data in Supporting Treatment Options
Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.
Richard Fisher
Latest:
Dr. Fisher on Bortezomib/R-CHOP Combo for Mantle Cell Lymphoma
Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.
Richard G. Gray, MA, MSc
Latest:
Richard Gray on a Longer Duration of Tamoxifen
Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.
Richard G. Stock, MD
Latest:
Dr. Stock on the Optimal Use of Radium-223 in mCRPC
Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer.
Richard Goldberg, MD
Latest:
Dr. Richard Goldberg on Pembrolizumab for Lynch Syndrome Patients
Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.
Richard JaeBong Lee, MD, PhD
Latest:
Dr. Lee Highlights Key Takeaways From SPARTAN Trial in M0CRPC
Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital, and assistant professor of medicine at Harvard Medical School, highlights key takeaways from the phase III SPARTAN trial in nonmetastatic castration-resistant prostate cancer.